REJECTED: FDA snubs Lilly/Boehringer SGLT2 inhibitor empagliflozin
This article was originally published in Scrip
Executive Summary
The FDA's rejection of the new drug application (NDA) for empagliflozin revealed on 5 March has put Boehringer Ingelheim and Lilly significantly further behind their competitors in bringing sodium glucose co-transporter-2 (SGLT2) inhibitors to the US marketplace for patients with type 2 diabetes.